Publications

Department of Medicine faculty members published more than 3,000 peer-reviewed articles in 2022.

Filter by

BMJ (Clinical research ed.)

Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.

2022

Authors: Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, McCoy RG

JAMA internal medicine

Analysis of Patient-Focused Information About Left Atrial Appendage Occlusion on US Hospital Web Pages.

2022

Authors: Dhruva SS, Ji RZ, Ross JS, Spatz ES, Redberg RF

JAMA network open

Post-Emergency Department Virtual Care-More Questions Than Answers.

2022

Authors: Wray CM

JAMA network open

Jane (or Dr Doe?) Will Reply to Your Patient Portal Message Now.

2022

Authors: Santhosh L, Witt L

JAMA internal medicine

Anesthesia Care for Cataract Surgery in Medicare Beneficiaries.

2022

Authors: Perumal D, Dudley RA, Gan S, Boscardin WJ, Gill A, Gelb AW, Lee SJ, Chen CL

Academic medicine : journal of the Association of American Medical Colleges

The Clinical Microsystems Clerkship at University of California, San Francisco: Integrating Clinical Skills and Health Systems Improvement for Early Medical Students.

2022

Authors: Chang A, Pierluissi E, Cornes S, Ishizaki A, Teherani A, Davis J, Hauer KE, Lucey CR

JAMA network open

COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods.

2022

Authors: Marquez C, Kerkhoff AD, Schrom J, Rojas S, Black D, Mitchell A, Wang CY, Pilarowski G, Ribeiro S, Jones D, Payan J, Manganelli S, Rojas S, Lemus J, Jain V, Chamie G, Tulier-Laiwa V, Petersen M, DeRisi J, Havlir DV

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

HIV and Cardiac End-Organ Damage in Women: Findings from an Echocardiographic Study Across the United States.

2022

Authors: Shitole SG, Lazar JM, Taub CC, Furlani AC, Konkle-Parker DJ, Dionne-Odom J, Fischl MA, Ofotokun I, Adimora AA, Topper EF, Golzar Y, Kassaye SG, Gustafson D, Anastos K, Hanna DB, Xue X, Tien PC, Kaplan RC, Kizer JR

Volume 33 of Issue 11 | Journal of cardiovascular electrophysiology

Sacubitril/valsartan: An antiarrhythmic drug?

2022

Authors: Huang E, Bernard ML, Elise Hiltbold A, Khatib S, Polin GM, Rogers PA, Dominic P, Morin DP

View Abstract

INTRODUCTION

Heart failure (HF) is a major cause of morbidity and mortality, with nearly half of all HF-related deaths resulting from sudden cardiac death (SCD), most often from an arrhythmic event. The pathophysiologic changes that occur in response to the hemodynamic stress of HF may lead to increased arrhythmogenesis. Theoretically, medications that block these arrhythmogenic substrates would decrease the risk of SCD. The combined angiotensin receptor and neprilysin inhibitor (ARNi; tradename Entresto) is the newest commercially available medication for the treatment of heart failure.

METHODS AND RESULTS

We reviewed and synthesized the available literature regarding sacubitril/valsartan and its effects on cardiac rhythm. ARNi has been shown to decrease cardiovascular mortality and hospitalization in patients with HF with reduced ejection fraction (HFrEF). Emerging evidence suggests that ARNi also may play a role in reducing arrhythmogenesis and thereby SCD.

CONCLUSION

This review summarizes the current data regarding this ARNi and its potential antiarrhythmic effects.

View on PubMed

European journal of heart failure

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction.

2022

Authors: van Essen BJ, Tromp J, Ter Maaten JM, Greenberg BH, Gimpelewicz C, Felker GM, Davison BA, Severin T, Pang PS, Cotter G, Teerlink JR, Metra M, Voors AA